How to Prepare Clinical Evaluation Materials for Medical Device Registration in Thailand?

Direct answer: Preparing clinical evaluation materials for medical device registration in Thailand normally begins with confirming the product classification and the applicable registration pathway, and only then assembling the technical file, labels and instructions for use, quality management system evidence, authorization documents and local representative documents. Existing NMPA documentation can serve as a basis, but it usually has to be adapted to Thai FDA requirements in terms of language, format, labelling and evidence chain. For Chinese manufacturers, the safer approach is to complete a product classification and documentation gap assessment first, and then determine whether NMPA, CE, FDA, ISO 13485 or other market materials can be reused.

Scope and Core Question

Companies searching for guidance on how to prepare clinical evaluation materials for Thailand registration are usually not looking for a conceptual explanation. They need to judge whether their existing documentation can support a Thai submission, whether a local agent or authorized representative is required, why timelines may be extended, and which issues could affect launch plans. Behind this question there are usually several linked topics: product classification, registration pathway, evidence chain, labelling localization and post-market maintenance responsibilities.

If a company plans to enter several GHWP member states or markets in Southeast Asia, the Middle East and Latin America at the same time, answering only one country's process is not enough. A more valuable approach is to first build reusable versions of the core technical file, quality system evidence, performance verification, clinical evidence and labels/IFU, and then localize them according to each country's regulatory requirements.

Registration Decision Logic

Companies should first confirm the intended use, mechanism of action, use scenario, body contact type, duration of use, sterility, whether the device is active, and whether it includes software or IVD attributes, and then determine the risk class and submission pathway. If the pathway is judged incorrectly, subsequent translation, notarization, authorization, testing and supplementary documentation will all move in the wrong direction.

For a Thailand project, it is also necessary to confirm the applicant entity and the boundaries of local responsibility: who holds the certificate, who handles regulatory communications, who manages importation and post-market events, who triggers changes, and who maintains renewal documentation. If these points are left vague in a commercial contract, market control can easily be affected later.

Materials and Evidence

Typical documentation includes product description, model and specification matrix, intended use, risk classification rationale, ISO 13485 or applicable quality system evidence, technical file, performance verification reports, risk management file, clinical evaluation or clinical evidence, labels and IFU, authorization documents, existing registration certificates, manufacturer declarations and post-market surveillance documentation.

The key to documentation quality is not volume but consistency. IFU claims, the models covered by test reports, the scope of clinical evidence, risk management conclusions, label warnings and the information in the registration application form must support one another. Regulators focus on whether the device is safe, effective and traceable for its intended use, not on how many documents a company has uploaded.

Common Errors

• Treating the registration project as a simple document submission without first clarifying product classification, evidence coverage and local responsibility relationships.
• Submitting translated NMPA documents directly without restructuring the evidence according to the Thai pathway.
• Having too many models and specifications while test reports, clinical evidence or labels do not cover them adequately.
• Selecting a local agent purely on sales cooperation without defining regulatory responsibility, certificate control and post-market maintenance duties.
• Inconsistency between labels, IFU, promotional materials and registration claims, leading to deficiency letters or post-market compliance risk.
• Failing to plan multi-country document reuse in advance, resulting in repeated preparation for every country and inflated cost and timelines.

Company Preparation Checklist

Before launching the project, companies are advised to use an internal checklist to confirm the documentation basis, so that critical evidence gaps are not discovered only after submission.

• Compile the target product list, model and specification matrix, and intended use statements.
• Verify whether existing NMPA, CE, FDA or other market registration documents can be reused.
• Prepare the ISO 13485 certificate, test reports, risk management file, clinical evaluation and English IFU.
• Confirm the duties, fees, certificate control and exit mechanisms of the local agent or authorized representative.
• Create a target-country gap assessment table identifying what must be re-tested, translated, notarized or supplemented with declarations.

AIMEILI Perspective

AIMEILI advises companies not to view Thailand registration as a one-off document submission, but to manage it as an overseas market access project. For companies preparing to enter multiple countries, building one clear core technical file and evidence matrix first and then converting it to each country's requirements is usually faster, more stable and more conducive to later changes and renewals than patching documents country by country.

From a project management perspective, three things should be controlled early: first, product classification and pathway determination; second, consistency of the documentation evidence chain; and third, the regulatory responsibility boundaries of local partners. If these three points are unclear, the project may still face repeated deficiency responses, agent communication problems and post-market maintenance issues, even if the documentation appears extensive.

Frequently Asked Follow-Up Questions

Can domestic Chinese documentation be used directly for Thai registration?

Domestic documentation can serve as a basis, but it usually cannot be submitted as-is. Companies need to adjust the document structure, language, labelling, authorization documents and evidence chain according to local regulatory requirements.

When is the best time to start a gap assessment?

It is recommended to start immediately after confirming the target markets and product list. The earlier the gap assessment is completed, the easier it is to arrange re-testing, translation, label adjustments and agent selection in advance.

Why does the choice of local agent affect registration quality?

The local agent typically participates in registration communication, changes, renewals and post-market event handling. Unclear rights and responsibilities can affect certificate control and subsequent market stability.

Quality System and Evidence Consistency

From a review perspective, quality system documentation is not an isolated certificate. Regulators usually examine whether the manufacturer name, manufacturing site, product scope, certificate validity period, applicable standards and technical file are consistent. If the scope of the ISO 13485 certificate does not match the products being submitted, or if the manufacturing site, model specifications or IFU version do not align with test reports, the company may be asked for supplementary explanations even if it has prepared a large volume of documents.

Companies should establish an evidence consistency checklist before submission, mapping product name, model and specification, intended use, applicable standards, test report numbers, clinical evaluation conclusions, risk management version, label and IFU version, and quality system certificate item by item. This may appear basic, but it can significantly reduce the probability of deficiency letters, especially for projects submitting to multiple GHWP member states or for multiple product families at the same time.

Localization and Agent Responsibilities

Thailand registration projects usually involve arrangements for a local agent, authorized representative, importer or registration holder. Companies need to confirm in advance whether the local partner is only responsible for submitting documents, or also for regulatory communication, certificate maintenance, post-market event reporting, change applications and renewal reminders. Different responsibility boundaries directly affect certificate control and subsequent market stability.

Labels, IFU and authorization documents also cannot simply be translated. Companies should verify local language requirements, product claim boundaries, warnings, storage and transport conditions, UDI or traceability requirements, importer information, authorized representative information and after-sales contact details. For companies that already hold CE, FDA, NMPA or other market documentation, the focus of localization is to convert reusable evidence into a submission structure acceptable to the target country, rather than writing an entirely separate set of documents.

Post-Market Maintenance and Long-Term Planning

Registration approval does not mean compliance work is finished. Companies also need to maintain certificate validity, change records, distributor authorizations, complaint handling, adverse event reporting, recall procedures, label versions and regulatory update records. Many companies invest heavily in obtaining approval but neglect post-market maintenance; when a manufacturing site change, model expansion, IFU update or agent replacement occurs later, the certificate and market sales can easily become disconnected.

AIMEILI recommends managing this issue within an annual international registration plan: first clarify target market priorities, then build a reusable document package and a country gap list, and finally schedule submission, deficiency responses, post-market maintenance and renewal milestones. The value of this is not only improving registration efficiency in a single country, but also enabling the company to build a replicable compliance capability for going global, reducing the cost of starting document preparation from scratch each time it enters a new market.

Further Reading

• Previous: How to Localize Labels and Instructions for Use for Medical Device Registration in Thailand?
• Next: Can Test Reports Be Reused for Medical Device Registration in Thailand?

Recommended Reading

• How to Prepare Registration Documents for Medical Device Registration in Malaysia?
• How to Determine Product Classification for Medical Device Registration in Malaysia?
• How to Organize the Technical File for Medical Device Registration in Malaysia?
• How to Localize Labels and Instructions for Use for Medical Device Registration in Malaysia?
• How to Prepare Clinical Evaluation Materials for Medical Device Registration in Malaysia?
• Can Test Reports Be Reused for Medical Device Registration in Malaysia?

About This Article

Published: 10 July 2026, 11:55 · Updated: 10 July 2026, 11:55

This article addresses priority questions that companies need to assess in practical medical device international registration projects, covering documentation preparation, compliance pathways and post-market maintenance.

Content author: AIMEILI Regulatory Editorial Team
Professional review: AIMEILI Medical Device International Registration Project Team
Source policy: Priority is given to official regulatory authorities, international organizations, standards bodies and publicly available regulatory materials; industry media and project experience are used only as supporting references.
Scope of application: This article is intended for preliminary understanding, documentation preparation and project planning. It does not replace the formal requirements of the target country's regulatory authority, testing conclusions or legal advice.

Source note: Compiled from AIMEILI's regulatory practice question bank, medical device international registration knowledge base and publicly available regulatory information; specific projects should be based on the latest requirements of the target country's regulatory authority and the product documentation basis.